Overview

Nedosiran in Pediatric Patients From Birth to 5 Years of Age With PH and Relatively Intact Renal Function

Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate nedosiran in participants 5 years of age and younger who have Primary Hyperoxaluria with relatively intact renal function.
Phase:
Phase 2
Details
Lead Sponsor:
Dicerna Pharmaceuticals, Inc.